Andrew Huberman joins Hims & Hers Health board as a director
As seen on the 24/7 Wall St. homepage on November 12, 2026.
One of the most-followed voices in health and longevity now sits on the board of a $4.5 billion telehealth company fighting for credibility as regulators tighten the screws on compounded GLP-1s. That is a distribution and trust asset rivals cannot buy, and it lands while the weight-loss price war is still escalating.
Continue ReadingShow less
Andrew Huberman, one of the most widely followed voices in health and longevity, was appointed to the board of Hims & Hers Health as a director on November 12, 2026. The company carries a market valuation of roughly $4.5 billion and operates as a telehealth platform competing in one of the most contested corners of consumer healthcare.
Regulators have been tightening their grip on compounded GLP-1 medications, a business line that has been central to the weight-loss price war now playing out across telehealth. Hims & Hers is fighting to hold its ground in that environment, and credibility with health-conscious consumers is a meaningful part of that fight.
Sponsored
That is precisely what a Huberman board seat can supply. His audience is built on trust in evidence-based health information, which is exactly the currency Hims & Hers needs as it tries to distinguish itself from rivals in a crowded, scrutinized market. That kind of distribution and trust is not something a competitor can replicate by writing a check.
What to watch now is whether the appointment translates into tangible commercial reach, particularly as the regulatory picture around compounded weight-loss drugs continues to evolve. A board seat is a signal, and in a market where perception shapes patient acquisition, that signal carries real weight.
Sources
Mentioned: HIMS